IP Library › Granted Patent US 7,696,227
Granted Patent B2
US 7,696,227 · App. 12/101,680 · Granted Apr 13, 2010

Small-molecule inhibitors of the androgen receptor

Assignee: Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,696,227
App. No.
12/101,680
Granted
Apr 13, 2010
Kind
B2
Abstract

The present invention provides a method of inhibiting an androgen receptor by administering a compound of Formula I: or a compound of Formula II: wherein R 1 , R 2 , R 3 and R 8 are each independently hydrogen or C 1-6 alkyl. R 4 is absent or is hydrogen, C 1-6 alkyl or C 1-6 alkyl-OH. R 5 is hydrogen, C 1-6 alkyl or —NR 6 R 7 . R 6 and R 7 are each independently hydrogen or C 1-6 alkyl, or are combined with the nitrogen to which they are attached to form a heterocycloalkyl having from 5 to 7 ring members. L is a linker of C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene or C 3-6 cycloalkylene. The compounds of Formula I include the salts, hydrates and prodrugs thereof. Each R 9 is H, C 1-6 alkyl, —OH or —O—C 1-6 alkyl. The compounds of Formulas I and II include the salts, hydrates and prodrugs thereof. By administering the compound of Formula I or II, the method inhibits the androgen receptor.

Claims (15)

1. A compound of Formula Ic:

wherein

the dashed line is absent;

R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen and C 1-6 alkyl;

R 4 is a member selected from the group consisting of hydrogen, C 1-6 alkyl and C 1-6 alkyl-OH;

R 5 is a member selected from the group consisting of hydrogen, C 1-6 alkyl and -NR 6 R 7 ;

R 6 and R 7 are each independently selected from the group consisting of hydrogen and C 1-6 alkyl, or are combined with the nitrogen to which they are attached to form a heterocycloalkyl having from 5 to 7 ring members;

and salts thereof.

2. The compound of claim 1 , wherein

R 1 is H; and

R 2 , R 3 , R 4 and R 5 are each C 1-6 alkyl.

3. The compound of claim 1 , wherein the compound is:

4. The compound of claim 1 , wherein the salt forms comprise a counterion selected from the group consisting of pamoate, chloride, bromide, succinate, maleate and acetate.

5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

6. The composition of claim 5 , wherein the composition is suitable for topical, injectible or oral administration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2008
From: DIAMOND, MARC; JONES, JEREMY; RENSLO, ADAM
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 021089/0154 →
Continuity (2)
Provisional Application 6091157800 · Apr 13, 2007
Related Publication 20080293766A1 · Nov 27, 2008